Abstract: Disclosed herein is a system and a method of providing access to at least one password protected device (D1-D5) via a password management system (100). The password management system (100) comprises first and second password management servers (200), each comprising a memory for storing an active password and a reserve password. The first and second password management servers (200) communicate the active and reserve passwords via a communication link (220). Either one of the first and second password management servers (200) requests access to the password protected device using the active password stored in the memory, and if the active password does not provide access, requests access using the reserve password.

Abstract: A cuffed tracheal tube has a shaft (10) with an inner component (30) having an inflation lumen (23) extending along a rib (33) along the outside of the component. The rib (33) terminates a short distance rearwardly of the patient end (14) of the inner component. The inflation lumen (23) is closed by an outer layer (51) applied over the inner component (30) and covering the patient end of the rib. Two closely spaced openings (54) through the rib (33) are spaced in the inflatable region of a silicone sealing cuff (13) secured around the patient end of the shaft.

Abstract: Non-human animals comprising a human or humanized IL-4 and/or IL-4R? nucleic acid sequence are provided. Non-human animals that comprise a replacement of the endogenous IL-4 gene and/or IL-4R? gene with a human IL-4 gene and/or IL-4R? gene in whole or in part, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized IL-4 gene under control of non-human IL-4 regulatory elements is also provided, including non-human animals that have a replacement of non-human IL-4-encoding sequence with human IL-4-encoding sequence at an endogenous non-human IL-4 locus. Non-human animals comprising a human or humanized IL-4R? gene under control of non-human IL-4R? regulatory elements is also provided, including non-human animals that have a replacement of non-human IL-4R?-encoding sequence with human or humanized IL-4R?-encoding sequence at an endogenous non-human C IL-4R? locus.

Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.

Abstract: A method is provided that can include activating at least two wireless communication channels in parallel, between a first wireless transceiver and a second wireless transceiver. Each of the at least two wireless communication channels can operate at a different radio carrier frequency, and the first wireless transceiver may be part of a first vehicle. The method can also include transmitting, by the first wireless transceiver, common information in parallel on the at least two wireless communication channels to the second wireless transceiver and deactivating the at least two wireless communication channels.

Abstract: Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.

Abstract: The present invention provides new products using mucilaginous seeds as binders.

Abstract: An automated damping system including a damping device arranged and disposed to provide variable resistance to a load. The variable resistance provides resistance values corresponding to a displacement position of the damping device. The system includes a damping profile generator that calculates a damping profile and a sensor is arranged and disposed to measure one or more damping affecting properties. The sensor provides the one or more damping affecting properties to the damping profile generator. The damping profile provides the variable resistance based upon the one or more damping affecting properties of the load.

Abstract: A method for forming a fiber-reinforced thermoplastic control surface includes forming first and second skins from a fiber-reinforced thermoplastic resin. The method further includes overmolding fiber-reinforced thermoplastic features onto the first skin and/or second skin, including stiffener structures, sidewalls, and/or hinges. The method further comprises welding or consolidating the first and second skins together, along with the associated internal features overmolded thereon to form a single-piece, stiffened, fiber-reinforced thermoplastic control surface.

Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

Abstract: Genetically modified non-human animals expressing human EPO from the animal genome are provided. Also provided are methods for making non-human animals expressing human EPO from the non-human animal genome, and methods for using non-human animals expressing human EPO from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human erythropoiesis and erythrocyte function; in modeling human pathogen infection of erythrocytes; in in vivo screens for agents that modulate erythropoiesis and/or erythrocyte function, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to erythrocytes or erythrocyte progenitors; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on erythrocytes or erythrocyte progenitors; in in vivo screens of erythrocytes or erythrocyte progenitors from an individual to predict the responsiveness of an individual to a disease therapy.

Abstract: Mice, embryos, cells, and tissues having a restricted immunoglobulin heavy chain locus and an ectopic sequence encoding one or more ADAM6 proteins are provided. In various embodiments, mice are described that have humanized endogenous immunoglobulin heavy chain loci and are capable of expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof that is functional in a male mouse. Mice, embryos, cells, and tissues having an immunoglobulin heavy chain locus characterized by a single human VH gene segment, a plurality of human DH gene segments and a plurality of human JH gene segments and capable expressing an ADAM6 protein or ortholog or homolog or functional fragment thereof are also provided.

Abstract: The present invention relates to a confectionery composition that has the necessary stability and texture to be used as filling in foodstuffs, preferably chocolate confectionery products.

Abstract: Disclosed herein is a system and a method of providing access to at least one password protected device (D1-D5) via a password management system (100). The password management system (100) comprises first and second password management servers (200), each comprising a memory for storing an active password and a reserve password. The first and second password management servers (200) communicate the active and reserve passwords via a communication link (220). Either one of the first and second password management servers (200) requests access to the password protected device using the active password stored in the memory, and if the active password does not provide access, requests access using the reserve password.

Abstract: Provided herein are methods of treating or preventing a fungal colonisation or infection in a subject. The method includes administering a therapeutically effective amount of a compound, or a therapeutically acceptable salt thereof, to the subject, wherein the fungal colonisation or infection is caused by a fungal agent.

Abstract: Quantum processing devices and methods for shuttling qubits between a pair of processing elements are disclosed. In particular, a disclosed method for shuttling a qubit from a first processing element to a second processing element in a quantum processing device comprising a plurality of processing elements, includes: applying an optimal bias configuration between the first processing element and the second processing element to shuttle the qubit from the first processing element to the second processing element in a manner that minimizes the time spent by the qubit in one or more state transition points between the first processing element and the second processing element.

Abstract: The present invention relates to amorphous porous particles comprising sugar, a bulking agent and surfactant, having a closed porosity of between 20 to 60% a sphericity of at least between 0.8 and 1. In a further aspect the present invention relates to a process of making said amorphous porous particles and their use as bulk sugar replacers in food products such as fat based confectionery products for example, chocolate.

Abstract: A method and a system are for sparse sampling utilizing a programmatically randomized signal for modulating a carrier signal. The system includes a compound sparse sampling pattern generator that generates at least one primary carrier signal, and at least one secondary signal. The at least one secondary signal modulates the at least one primary signal in a randomized fashion.